PURPOSE: This analysis describes the long-term workforce participation patterns of individuals diagnosed with head and neck cancer (HNC). METHODS: Survivors of HNC (ICD10 C00-C14, C32) diagnosed at least 8 months previously were identified from the National Cancer Registry Ireland and sent a survey including questions about working arrangements before and since diagnosis. Descriptive statistics and multivariate logistic regression were used to examine the factors that influence workforce participation at 0, 1 and 5 years after diagnosis. RESULTS: Two hundred sixty-four individuals employed at the time of diagnosis responded to the survey, an average 6 years post-diagnosis. Seventy-seven percent took time off work after diagnosis, with a mean work absence of 9 months (range 0-65 months). Fifty-two percent of participants reduced their working hours (mean reduction 15 h/week). The odds of workforce participation following HNC were increased by not being eligible for free medical care (OR 2.61, 95% CI 1.15-5.94), having lip, mouth or salivary gland cancer (compared to cancer of the pharynx or cancer of the larynx, OR 2.79, 1.20-6.46), being self-employed (OR 2.01, 1.07-3.80), having private health insurance (OR 2.06, 1.11-3.85) and not receiving chemotherapy (OR 2.82, 1.31-6.06). After 5 years, only the effect of medical card remained (i.e., medical insurance) (OR 4.03, 1.69-9.62). CONCLUSIONS: Workforce participation patterns after HNC are complex and are influenced by cancer, treatment and employment factors. IMPLICATIONS FOR CANCER SURVIVORS: Patients should be informed of the potential impacts of HNC on workforce participation, and clinicians, policy makers and employers should be aware of these potential longer-term effects and related variables.
PURPOSE: This analysis describes the long-term workforce participation patterns of individuals diagnosed with head and neck cancer (HNC). METHODS: Survivors of HNC (ICD10 C00-C14, C32) diagnosed at least 8 months previously were identified from the National Cancer Registry Ireland and sent a survey including questions about working arrangements before and since diagnosis. Descriptive statistics and multivariate logistic regression were used to examine the factors that influence workforce participation at 0, 1 and 5 years after diagnosis. RESULTS: Two hundred sixty-four individuals employed at the time of diagnosis responded to the survey, an average 6 years post-diagnosis. Seventy-seven percent took time off work after diagnosis, with a mean work absence of 9 months (range 0-65 months). Fifty-two percent of participants reduced their working hours (mean reduction 15 h/week). The odds of workforce participation following HNC were increased by not being eligible for free medical care (OR 2.61, 95% CI 1.15-5.94), having lip, mouth or salivary gland cancer (compared to cancer of the pharynx or cancer of the larynx, OR 2.79, 1.20-6.46), being self-employed (OR 2.01, 1.07-3.80), having private health insurance (OR 2.06, 1.11-3.85) and not receiving chemotherapy (OR 2.82, 1.31-6.06). After 5 years, only the effect of medical card remained (i.e., medical insurance) (OR 4.03, 1.69-9.62). CONCLUSIONS: Workforce participation patterns after HNC are complex and are influenced by cancer, treatment and employment factors. IMPLICATIONS FOR CANCER SURVIVORS: Patients should be informed of the potential impacts of HNC on workforce participation, and clinicians, policy makers and employers should be aware of these potential longer-term effects and related variables.
Authors: L B Harrison; M J Zelefsky; D G Pfister; E Carper; A Raben; D H Kraus; E W Strong; A Rao; H Thaler; T Polyak; R Portenoy Journal: Head Neck Date: 1997-05 Impact factor: 3.147
Authors: Emily C Dowling; Neetu Chawla; Laura P Forsythe; Janet de Moor; Timothy McNeel; Heather M Rozjabek; Donatus U Ekwueme; K Robin Yabroff Journal: Cancer Date: 2013-06-21 Impact factor: 6.860
Authors: Michael Feuerstein; Briana L Todd; Michal C Moskowitz; Gina L Bruns; Mallori R Stoler; Thomas Nassif; Xinhua Yu Journal: J Cancer Surviv Date: 2010-10-14 Impact factor: 4.442
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: Paul Hanly; Rebecca Maguire; Myles Balfe; Philip Hyland; Aileen Timmons; Eleanor O'Sullivan; Phyllis Butow; Linda Sharp Journal: Support Care Cancer Date: 2016-05-16 Impact factor: 3.603
Authors: Steffen Torp; Alain Paraponaris; Elke Van Hoof; Marja-Liisa Lindbohm; Sietske J Tamminga; Caroline Alleaume; Nick Van Campenhout; Linda Sharp; Angela G E M de Boer Journal: J Occup Rehabil Date: 2019-06
Authors: Janet S de Moor; Catherine M Alfano; Erin E Kent; Wynne E Norton; Diarmuid Coughlan; Megan C Roberts; Melvin Grimes; Cathy J Bradley Journal: J Natl Cancer Inst Date: 2018-10-01 Impact factor: 13.506
Authors: Merel de Jong; Sietske J Tamminga; Angela G E M de Boer; Monique H W Frings-Dresen Journal: J Cancer Surviv Date: 2015-09-14 Impact factor: 4.442
Authors: Merel de Jong; Sietske J Tamminga; Angela G E M de Boer; Monique H W Frings-Dresen Journal: BMC Health Serv Res Date: 2016-06-02 Impact factor: 2.655